• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Helicobacter pylori infection and antibiotic resistance: a WHO high priority?幽门螺杆菌感染和抗生素耐药性:世卫组织的高度优先事项?
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):383-384. doi: 10.1038/nrgastro.2017.57. Epub 2017 May 3.
2
Drugs for Helicobacter pylori infection.用于幽门螺杆菌感染的药物。
Med Lett Drugs Ther. 2017 Jul 17;59(1525):113-117.
3
How We Approach Difficult to Eradicate Helicobacter pylori.我们如何应对难以根除的幽门螺杆菌。
Gastroenterology. 2022 Jan;162(1):32-37. doi: 10.1053/j.gastro.2021.10.048. Epub 2021 Nov 3.
4
Illusions regarding clinical trials and treatment guidelines.关于临床试验和治疗指南的错觉。
Gut. 2017 Dec;66(12):2043-2046. doi: 10.1136/gutjnl-2017-314744. Epub 2017 Sep 21.
5
Treatment of Helicobacter pylori infection: Where are we now?幽门螺杆菌感染的治疗:我们目前的进展如何?
J Gastroenterol Hepatol. 2016 Dec;31(12):1918-1926. doi: 10.1111/jgh.13418.
6
Treatment of Helicobacter pylori infection.幽门螺杆菌感染的治疗。
BMJ. 2008 Sep 15;337:a1454. doi: 10.1136/bmj.a1454.
7
[First line eradication treatment of Helicobacter pylori in 2019].2019年幽门螺杆菌的一线根除治疗
Rev Med Suisse. 2019 Oct 16;15(667):1854-1858.
8
Hybrid Therapy as First-Line Regimen for Helicobacter pylori Eradication in Populations with High Antibiotic Resistance Rates.混合疗法作为高抗生素耐药率人群幽门螺杆菌根除的一线治疗方案
Helicobacter. 2016 Oct;21(5):382-8. doi: 10.1111/hel.12294. Epub 2016 Jan 25.
9
[Prevalence of resistance to antimicrobial agents of H. pylori].[幽门螺杆菌对抗菌药物的耐药率]
Arch Pediatr. 2010 Jun;17(6):816-7. doi: 10.1016/S0929-693X(10)70126-3.
10
Clarithromycin resistance in Helicobacter pylori infection: does it matter?幽门螺杆菌感染中的克拉霉素耐药性:有关系吗?
J Gastroenterol Hepatol. 2000 Oct;15(10):1089-92. doi: 10.1046/j.1440-1746.2000.02362.x.

引用本文的文献

1
Molecular Detection of Multiple Antimicrobial Resistance Genes in -Positive Gastric Samples from Patients Undergoing Upper Gastrointestinal Endoscopy with Gastric Biopsy in Algarve, Portugal.葡萄牙阿尔加维地区接受上消化道内镜检查并行胃活检的患者阳性胃样本中多种抗菌药物耐药基因的分子检测
Antibiotics (Basel). 2025 Aug 1;14(8):780. doi: 10.3390/antibiotics14080780.
2
Fecal microbiota transplantation from Helicobacter pylori carriers following bismuth quadruple therapy exacerbates alcohol-related liver disease in mice via LPS-induced activation of hepatic TLR4/NF-κB/NLRP3 signaling.铋剂四联疗法后幽门螺杆菌携带者的粪便微生物群移植通过脂多糖诱导的肝脏TLR4/NF-κB/NLRP3信号激活加重小鼠酒精性肝病。
J Transl Med. 2025 Jun 3;23(1):627. doi: 10.1186/s12967-025-06573-5.
3
Genetic Basis of Gap Formation Between Migrating Colonies in Soft Agar Assays.软琼脂试验中迁移菌落间间隙形成的遗传基础。
Microorganisms. 2025 May 7;13(5):1087. doi: 10.3390/microorganisms13051087.
4
Guideline-based bismuth quadruple therapy for helicobacter pylori infection in China: A systematic review and network meta-analysis.中国基于指南的铋剂四联疗法治疗幽门螺杆菌感染:一项系统评价和网络荟萃分析
PLoS One. 2025 Feb 20;20(2):e0318937. doi: 10.1371/journal.pone.0318937. eCollection 2025.
5
Helicobacter pylori Infection in Colombia: Phylogeny, Resistome, and Virulome.哥伦比亚的幽门螺杆菌感染:系统发育、耐药基因组和毒力基因组
APMIS. 2025 Feb;133(2):e70003. doi: 10.1111/apm.70003.
6
M cells targeted H. pylori antigen SAM-FAdE displayed on bacterium-like particles induce protective immunity.靶向显示在类细菌颗粒上的幽门螺杆菌抗原SAM-FAdE的M细胞可诱导保护性免疫。
J Nanobiotechnology. 2025 Jan 18;23(1):23. doi: 10.1186/s12951-025-03111-9.
7
Crises in Antimicrobial Stewardship: Misuse of Clarithromycin for Therapy.抗菌药物管理危机:克拉霉素治疗的不当使用
Pharmacoepidemiology. 2024 Mar;3(1):82-93. doi: 10.3390/pharma3010006. Epub 2024 Feb 20.
8
Genetic Determinants of Clarithromycin and Fluoroquinolones Resistance in in Serbia.塞尔维亚克拉霉素和氟喹诺酮类耐药性的遗传决定因素
Antibiotics (Basel). 2024 Oct 1;13(10):933. doi: 10.3390/antibiotics13100933.
9
Synergistic effects of novel penicillin-binding protein 1A amino acid substitutions contribute to high-level amoxicillin resistance of .新型青霉素结合蛋白 1A 氨基酸取代的协同作用导致 对阿莫西林的高水平耐药性。
mSphere. 2024 Aug 28;9(8):e0008924. doi: 10.1128/msphere.00089-24. Epub 2024 Aug 1.
10
Self-Correcting Method for Highly Effective Office-Based Helicobacter pylori Therapy Using Cumulative Test of Cure Data.基于累积治愈测试数据的高效门诊幽门螺杆菌治疗的自我校正方法。
Helicobacter. 2024 Jul-Aug;29(4):e13112. doi: 10.1111/hel.13112.

本文引用的文献

1
Treating Helicobacter pylori effectively while minimizing misuse of antibiotics.有效治疗幽门螺杆菌,同时最大限度减少抗生素滥用。
Cleve Clin J Med. 2017 Apr;84(4):310-318. doi: 10.3949/ccjm.84a.14110.
2
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.美国胃肠病学会临床指南:幽门螺杆菌感染的治疗
Am J Gastroenterol. 2017 Feb;112(2):212-239. doi: 10.1038/ajg.2016.563. Epub 2017 Jan 10.
3
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report.幽门螺杆菌感染的管理——马斯特里赫特 V/佛罗伦萨共识报告。
Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.
4
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.幽门螺杆菌根除的挽救治疗:铋剂四联疗法中阿莫西林或四环素的随机非劣效性试验
Am J Gastroenterol. 2016 Dec;111(12):1736-1742. doi: 10.1038/ajg.2016.443. Epub 2016 Sep 27.
5
The Toronto Helicobacter pylori Consensus in Context.多伦多幽门螺杆菌共识解读
Gastroenterology. 2016 Jul;151(1):9-12. doi: 10.1053/j.gastro.2016.05.009. Epub 2016 May 20.
6
Helicobacter pylori therapy: a paradigm shift.幽门螺杆菌治疗:范式转变。
Expert Rev Anti Infect Ther. 2016 Jun;14(6):577-85. doi: 10.1080/14787210.2016.1178065. Epub 2016 May 3.

幽门螺杆菌感染和抗生素耐药性:世卫组织的高度优先事项?

Helicobacter pylori infection and antibiotic resistance: a WHO high priority?

机构信息

VA Center for Innovations in Quality, Effectiveness and Safety (IQuESt), Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, Texas 77030, USA.

Department of Medicine, Michael E. DeBakey VA Medical Center and Baylor College of Medicine, RM 3A-318B (111D), 2002 Holcombe Boulevard, Houston, Texas 77030, USA.

出版信息

Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):383-384. doi: 10.1038/nrgastro.2017.57. Epub 2017 May 3.

DOI:10.1038/nrgastro.2017.57
PMID:28465548
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6905073/
Abstract

The WHO listed among 16 antibiotic-resistant bacteria that pose the greatest threat to human health. Given the alarmingly high antibiotic resistance rates, antibiotic stewardship programmes need to be developed and implemented. Future research should explore provider and systems-level barriers to antibiotic susceptibility testing.

摘要

世界卫生组织(WHO)列出了对人类健康构成最大威胁的 16 种抗药性细菌。鉴于抗生素耐药率高得惊人,需要制定和实施抗生素管理计划。未来的研究应探讨提供者和系统层面对抗生素药敏试验的障碍。